Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance

Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full-year 2026 financial guidance on January 8, reporting that the total net revenue is expected in the range of $1.125 billion to $1.195 billion, with the total SUBLOCADE® net revenue anticipated in the $905 million to $945 million range.

Management reported that 2025 marked a “transition year” for the company, characterised by the establishment of the Indivior Action Agenda and completion of Phase I – Generate Momentum. It is well-positioned to execute on Phase II – Accelerate in 2026, and expects to grow SUBLOCADE net revenue by 11% at the midpoint of its guidance range, while raising adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points.

Indivior PLC’s (NASDAQ:INDV) recent business highlights include its inclusion in the S&P SmallCap 600® index effective December 22, 2025. The company also attained shareholder approval of its proposal to change its domicile from the U.K. to the U.S. while establishing a new U.S. parent company, Indivior Pharmaceuticals, Inc. The change in domicile is anticipated to take effect on January 26, 2026. In addition, Indivior PLC (NASDAQ:INDV) paid in full the outstanding obligation of $295 million and concluded the legacy U.S. Department of Justice matter.

Indivior PLC (NASDAQ:INDV) develops, manufactures, and sells buprenorphine-based prescription drugs to treat opioid dependence. The company’s products include Suboxone Film, Suboxone Tablet, and Subutex Tablet, and its operations are divided into the following geographical segments: United States, Rest of World, and United Kingdom.

While we acknowledge the potential of INDV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.